Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829013 | 0.87 | SMN1; SMN2 (0.50) | ADORA2AADORA1HPGDALDH1A1NPC1 | |
| SCHEMBL829632 | 0.86 | POLB (0.53) | ADORA2AADORA1HPGDTSHRALDH1A1 | |
| SCHEMBL830346 | 0.84 | FAAH (0.53) | TSHRALDH1A1NPC1GAAHTR1A | |
| SCHEMBL829568 | 0.84 | GAA (0.60) | HPGDTSHRALDH1A1NPC1POLB | |
| SCHEMBL829334 | 0.81 | LIPE (0.56) | HPGDTSHRALDH1A1L3MBTL1TDP1 | |
| SCHEMBL830018 | 0.79 | LMNA (0.45) | TSHRL3MBTL1GAA | |
| SCHEMBL30928344 | 0.77 | SCN7A (0.50) | ADORA2AADORA1TSHRHRH3ALDH1A1 | |
| SCHEMBL829365 | 0.77 | LIPE (0.59) | ALDH1A1POLBL3MBTL1 | |
| SCHEMBL829467 | 0.75 | RAB9A (0.51) | HPGDTSHRALDH1A1NPC1POLB | |
| SCHEMBL5104855 | 0.75 | GAA (0.66) | ADORA2AADORA1TSHRALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | claimed |
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | VEGFA, FLT4, FLT1 | HTR3A 2596/4885ADORA2A 1749/4885ADORA1 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.